Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer |
| |
Authors: | P.F. Conte M.R. Sertoli M. Bruzzone A. Rubagotti R. Rosso G. Bentivoglio A. Conio G. Pescetto |
| |
Affiliation: | 1. Istituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica 1, Italy;2. Clinica Ostetrica Ginecologica dell''Universita, Genoa, Italy |
| |
Abstract: | A combination chemotherapy including cisplatin, 25 mg/m2 on Days 1,8; methotrexate, 30 mg/m2 on Day 1; and 5-fluorouracil, 600 mg/m2 on Day 1 has been evaluated in 28 previously untreated and 10 pretreated patients with advanced ovarian cancer after debulking surgery when feasible. The pathological response rates (complete + partial responses) were 69.2 and 50% in untreated and pretreated patients, respectively. Overall 24-month survival and progression-free survival (PFS) are 19.2 and 10.9%, respectively. A significant difference in survival and PFS is evident between patients with less and more than 2 cm residual disease and between responders (CR + PR) versus nonresponders. No renal toxicity was induced and no cycles had to be delayed because of hemathologic toxicity. |
| |
Keywords: | To whom correspondence should be addressed at: Clinica Ostetrica Ginecologica Università Viale Benedetto XV 10 16132 Genoa Italy. |
本文献已被 ScienceDirect 等数据库收录! |
|